Survival Extended With Pembrolizumab/Chemotherapy in Esophageal Cancer

February 3, 2021

Ken Kato, MD discusses the outcomes of the phase 3 KEYNOTE-590 study on esophageal cancer.

Ken Kato, MD, of the National Cancer Center Hospital in Tokyo, Japan discusses the outcomes of the phase 3 KEYNOTE-590 study on esophageal cancer.

The results, which were presented at the European Society of Medical Oncology (ESMO) Virtual Congress 2020, evaluated the efficacy of pembrolizumab plus chemotherapy versus chemotherapy alone as first-line treatment of patients with advanced esophageal cancer. The combination demonstrated improvements were seen in both progression-free survival and overall survival.

According to Kato, the safety profile was manageable. The confirmed overall response rate was 45% for the combination and 29.3% for the chemotherapy alone. The rate adverse effects for the combination was slightly higher for the combination, 72% and 68% for chemotherapy alone. The rate of discontinuation from drug-related adverse events was 19% for the combination and 12% for the chemotherapy alone.